生物组织支架用于开角型青光眼脉络膜上腔引流:手术操作与首例临床结果
这项首次人体试验纳入10例开角型青光眼合并白内障患者,在超声乳化白内障手术中植入永久性巩膜内脉络膜上腔生物支架以强化可控睫状体分离裂隙。术后12个月眼压平均降低40%至14.6±3.2 mm Hg,降眼压药物使用减少62%,生物组织植入物耐受良好且内皮安全性好。
要点
- 10例开角型青光眼合并白内障患者接受超声乳化联合脉络膜上腔生物支架植入,均成功植入且无显著并发症。
- 术后12个月平均眼压从基线24.2±6.9 mm Hg降低40%至14.6±3.2 mm Hg(p=0.004),80%患者眼压降低超过20%。
- 降眼压药物从基线平均1.3种减少62%至0.5种(p=0.037),12个月内皮细胞丢失仅11%。
核心结论
- 开角型青光眼患者行脉络膜上腔生物支架植入耐受良好、安全性好,可长期降低眼压并减少降眼压药物需求。
研究设计与样本
- 首次人体试验纳入10例开角型青光眼合并白内障患者(74.1±7.9岁),行超声乳化白内障手术联合植入永久性巩膜内脉络膜上腔生物支架以强化可控睫状体分离裂隙。
- 生物支架由脱细胞巩膜同种异体组织经微环钻制成聚合物管状植入物,术后随访12个月追踪眼压和抗青光眼药物使用。
主要发现
- 基线用药后平均眼压24.2±6.9 mm Hg,使用1.3±0.8种降眼压药物。
- 所有患者均成功植入生物支架,无显著并发症,术后即刻眼压下降并持续至1年。
- 12个月平均眼压从基线降低40%至14.6±3.2 mm Hg(p=0.004,配对双尾t检验),80%患者眼压降低超过20%。
- 生物支架使降眼压药物使用减少62%,从基线平均所需1.3种降至术后12个月0.5种(p=0.037)。
- 生物组织植入物耐受良好,内皮安全性好,联合超声乳化-生物支架术后12个月内皮细胞丢失仅11%,与单纯超声乳化术后预期相似;平均最佳矫正视力从基线20/130 Snellen提升至术后12个月20/36(p=0.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To report a first-in-human trial in open-angle glaucoma (OAG) subjects treated with a new microinterventional biostent-reinforced cyclodialysis technique to enhance supraciliary aqueous drainage. METHODS: Subjects (N=10; 74.1±7.9 years old) with OAG and cataracts underwent combined phacoemulsification cataract surgery with implantation of a permanent endoscleral supraciliary biostent to reinforce a controlled cyclodialysis cleft. The biostent comprised decellularised scleral allograft tissue microtrephined into a polymer tubular implant intraoperative/postoperative safety, intraocular pressure (IOP) and glaucoma medications were tracked through 12 months postimplantation. RESULTS: Baseline medicated IOP averaged 24.2±6.9 mm Hg with subjects using 1.3±0.8 IOP-lowering medications. Successful biostent implantation was achieved in all individuals without significant complications. Immediate IOP lowering was sustained through 1 year. Twelve-month mean IOP was reduced 40% from baseline to 14.6±3.2 mm Hg (p=0.004; paired two-tailed t-test), and 80% of patients achieved >20% IOP reduction. Biostenting reduced glaucoma medication use 62%, from a baseline mean of 1.3 required medications to 0.5 medications (p=0.037) at postoperative 12 months. The biotissue implant was well tolerated and demonstrated good endothelial safety with only 11% endothelial cell loss at 12 months after combined phaco-biostenting surgery, similar to that expected after phacoemulsification alone. Mean BCVA increased from baseline 20/130 Snellen to 20/36 at postoperative 12 months (p=0.001). CONCLUSION: Supraciliary biostenting in OAG patients is well tolerated, has a good safety profile and produces long-term IOP-lowering while reducing glaucoma medication requirements.
引用
- Ianchulev T, Weinreb RN, Kamthan G, et al. Biotissue stent for supraciliary outflow in open-angle glaucoma patients: surgical procedure and first clinical results of an aqueous drainage biostent. Br J Ophthalmol. 2024. PMID: 36593090. doi:10.1136/bjo-2022-322536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。